Event Date/Time: Oct 27, 2010 End Date/Time: Oct 28, 2010
Registration Date: Oct 27, 2010
Early Registration Date: Jul 23, 2010
Report as Spam


The treatment of neurological disorders has entered a new period of optimism. Previously considered largely untreatable, new insights into the underlying mechanisms of neurodegenerative disorders, has led to a flurry of activity and a host of new drugs in development. However, the major bottleneck, and the biggest barrier to commercial exploitation, is clinical development.

Clinical trials for CNS disorders have been riddled with errors for far too long. With 100s of millions of Euros being spent on every trial, it is now more important than ever to capitalise on research progress. The key to success is translating our ever growing pre-clinical knowledge of CNS disorders into well constructed, concise and most importantly conclusive clinical trials.

Inspired by the world's leading CNS drug developers (including Merck Serono, Johnson & Johnson, Novartis, AstraZeneca, Pfizer, Hoffman-La Roche, UCB, Merck & Co, Solvay and many other pioneering biotechs) Biorbis has developed an agenda that delivers practical value and provides a forum for frank and honest discussion about the key challenges facing the clinical development of neuro-drugs.

What's on the agenda for Advancing Clinical Trials in CNS?
Identifying Critical Biomarkers for Clinical Diagnosis and Disease Modification
Optimising Clinical Trial Design for Neuroscience Drug Development
Accelerating Clinical Development through Neuroimaging Strategies
Advancing Clinical Endpoints to Progress Development Strategies
Streamlining Global Clinical Operations to Reduce Attrition
Why should you attend Advancing Clinical Trials in CNS?
To understand the latest research efforts in neuro clinical trial design to streamline drug approval success.
To gain a multitude of new ideas and contacts to take back to your research organisation.
To learn how to accelerate progress of drug candidates through the clinic and maximise the speed to market for your neuro-drug.